Navigation Links
Express Genes by Eurofins MWG Operon Offers 4 Day Delivery of Synthetic Genes
Date:3/20/2013

Huntsville, AL (PRWEB) March 20, 2013

Eurofins MWG Operon announces the newest entry in their drive to provide ISO-quality research products and services ‘faster than ever.’ Synthetic genes are a rapidly expanding area of business and clients are anxious to accelerate their research in this highly-competitive field of investigation. Customers throughout the US and Canada can now order the new Express Gene service as late as 3:00 p.m. ET for completion just 4 days later - a full day earlier than any advertised service from competitors.

“We’re excited to share our advances in gene synthesis services with our clients. Delivering Express Genes in just 4 days is faster than our competitors are able to advertise. Express Genes joins Overnight DNA sequencing (available for all US locations) and Express Oligos further extending our efforts to be the fastest DNA Company in the US,” stated Martin Kunz, CEO of Eurofins MWG Operon Inc. “The new Express Genes service benefits the research of any institution or company pursuing development in fast cycles.”

“Express Genes is an exciting new offering," stated Helaman Escobar, Director of DNA Sequencing Operations at Eurofins MWG Operon Inc. “Advances in the laboratory have shortened our process for creating high-quality synthetic genes, which includes full DNA sequencing confirmation of the construct. These advances, and production of all gene synthesis under ISO 9001/13485 specifications, make Express Genes a highly competitive entry into the fastest growing segment of the DNA marketplace.” Visit operon.com/express-gene for more information about Express Gene synthetic gene services.

About Eurofins MWG Operon
Eurofins MWG Operon, a member of the Eurofins Group with major offices and production facilities in the United States, Europe, and Asia, is an international provider of DNA sequencing services, DNA synthesis products, and bioinformatics services for academic and industrial research. The company’s strengths are its strong customer orientation, fast service, and high quality. For additional information, please visit our website at operon.com.

For further information, contact:

Donna Brown
Eurofins MWG Operon
2211 Seminole Drive
Huntsville, Alabama 35805
Phone: (256) 799-5890
Email: donnabrown(at)eurofins(dot)com

Read the full story at http://www.prweb.com/releases/2013/3/prweb10548945.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
2. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
3. Veracyte Announces Medicare Coverage for Its Afirma® Gene Expression Classifier for Improved Thyroid Nodule Diagnosis
4. Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer
5. Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers
6. HemoShear Partners with Expression Analysis (EA) to Develop a Human Drug-Induced Vascular Response Database
7. Genedata Expressionist® Established as Data Analysis Platform for Oncological Research
8. Exon skipping to restore gene expression is promising therapeutic strategy for muscular dystrophy
9. Antigen Express AE37 Breast Cancer Vaccine Featured In "Micro-Cap Review" Interview
10. transOMIC technologies Releases Tagged ORF Clones for Protein Expression
11. Free Research Report on Dyax Corp., Ebix, Inc., 8x8, Inc., EnerSys and Express Scripts Holding Co.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the ... today the Clinical Reach Virtual Patient Encounter CONSULT module which enables both ... physician and clinical trial team. , Using the CONSULT module, patients and physicians can ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
Breaking Biology Technology:
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
Breaking Biology News(10 mins):